EarningsStraumann reported impressive market share gains in EMEA, driven by successful launches of the iEXCEL system in key countries like Germany, Spain, and Italy.
Financial PerformanceAPAC region demonstrated high-teen organic growth of 19.7%, which is supported by strong performance in both challenger and premium brands, suggesting a more structural growth pattern.
Stock RecommendationAnalyst reiterates a BUY rating with a CHF175.00 price target, showing confidence in Straumann's stock potential amid a favorable Medtech environment in the US, China, and EMEA.